Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma

Neuro-Oncology

Volumn 14, Issue 4, 2012, Pages 491-495

  Bailon, Olivier ^a,b   Chouahnia, Kader ^a   Augier, Alexandre ^a   Bouillet, Thierry ^a,c   Billot, Sgolne ^a,b   Coman, Irne ^a   Ursu, Rnata ^a   Belin, Catherine ^a   Zelek, Laurent ^a,b   Des Guetz, Gatan ^a   Levy, Christine ^c   Carpentier, Antoine F ^a,b   Morere, Jean Franois ^a,b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c Institut Radiologique des Hautes Energies   (France)

Author keywords

brain metastasis; carboplatin; chemotherapy; lung cancer; pemetrexed

Indexed keywords

CARBOPLATIN; PEMETREXED;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; EVENT FREE SURVIVAL; FATIGUE; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCYTOPENIA; RESPIRATORY DISTRESS SYNDROME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84859535445     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos004     Document Type: Article

References (33)

1. Klos KJ, O'Neill BP. Brain metastases. Neurologist. 2004;10:31-46. (Pubitemid 38140837)
2. Posner JB. Neurologic complications of systemic cancer. Dis Mon. 1978;25:1-60.
3. Takakura K, Keji S, Shuntaro H, Asao H. Treatment. In: Takakura K, Sano K, Hojo S, eds. Metastatic Tumors of the Central Nervous System. Tokyo: Igaku Shoin, 1982:195-257.
4. Sanchez de Cos J, Gonzalez MAS, Montero MV, et al. Non small cell lung cancer and silent brain metastasis survival and prognostic factors. Lung Cancer. 2009;63:140-145.
5. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500. (Pubitemid 20067825)
6. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583-590. (Pubitemid 23161878)
7. Schö ggl A, Kitz K, Reddy M, et al. Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of single brain metastases. Acta Neurochir (Wien). 2000;142:621-626.
8. O'Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O'Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys. 2003;55:1169-1176. (Pubitemid 36338280)
9. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Franç ais de Pneumo-Cancé rologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12:59-67. (Pubitemid 32162449)
10. Slotman B, Faivre-Finn C, Kramer G, et al. EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664-672. (Pubitemid 47267236)
11. Lee DH, Han JY, Kim HT, et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer. 2008;113:143-149.
12. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529-2536. (Pubitemid 46606335)
13. Stea B, Suh JH, Boyd AP, Cagnoni PJ, Shaw E; REACH Study Group. Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival. Int J Radiat Oncol Biol Phys. 2006;64:1023-1030.
14. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006;24:106-114. (Pubitemid 46630501)
15. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advance non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol. 2000;11:435-440. (Pubitemid 30333546)
16. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. 2001;92:595-600. (Pubitemid 32735195)
17. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005;104:2449-2456. (Pubitemid 41691567)
18. Ma CX, Nair S, Thomas S, et al. North Central Cancer Treatment Group; Mayo Clinic; Eli Lilly & Company. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23:5929-5937.
19. Bogart JA, Govindan R. A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. Clin Lung Cancer. 2006; 7:285-287. (Pubitemid 43280035)
20. Scagliotti GV, Park K, Patil S, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemona?̈ve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer. 2009;45:2298-2303.
21. Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;11:2466-2470.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
23. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003.
24. Ricciardi S, Tomao S, de Marinis F. Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. Ther Clin Risk Manag. 2009;5:781-787.
25. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. 2009;66:141-149.
26. Bearz A, Garassino I, Tiseo M, et al. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer. 2010;68:264-268.
27. Gaspar LE, Scott C, Murray K, CurranW. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000;47:1001-1006. (Pubitemid 30345599)
28. Kortmann RD, Jeremic B, Weller M, Plasswilm L, Bamberg M. Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol. 2003;179:219-232.
29. Minotti V, Crinò L, Meacci ML, et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer. 1998;20:93-98. (Pubitemid 28345190)
30. Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol. 1999;17:3522-3530. (Pubitemid 29517923)
31. Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology. 2000;59:291-295.
32. Cortot AB, Geriniè re L, Robinet G, et al. Groupe Lyon-Saint-Etienne d'Oncologie Thoracique; Groupe Franç ais de Pneumo-Cancé rologie. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol. 2006;17:1412-1417. (Pubitemid 44400379)
33. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005; 68:110-118. (Pubitemid 41002949)